Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Precision BioSciences Inc DTIL

Healthcare Biotechnology
Precision BioSciences, Inc. is an advanced gene editing company dedicated to improving life (DTIL) with its proprietary ARCUS genome editing platform. Using ARCUS, the Company's pipeline consists of in vivo gene editing candidates designed to deliver cures for a range of genetic and infectious diseases. The ARCUS platform develops in vivo gene editing therapies for gene edits, including gene... see more

Recent & Breaking News (NDAQ:DTIL)

Precision BioSciences Reports Clinical Program Updates for Its Allogeneic CAR T Pipeline

Business Wire December 11, 2021

Precision BioSciences to Host Virtual Webcast and Conference Call to Review Interim Phase 1/2a PBCAR0191 CAR T Data and Provide CAR T Program Updates on Saturday, December 11, 2021

Business Wire December 6, 2021

Precision BioSciences to Present Preclinical Gene Editing Data on its ARCUS-Based Chronic Hepatitis B Program at the HEP DART 2021 Conference

Business Wire December 3, 2021

Precision BioSciences Reports Third Quarter 2021 Financial Results and Provides Business Update

Business Wire November 10, 2021

Precision BioSciences to Highlight Capabilities of ARCUS Gene Editing for Allogeneic CAR T Cell Immunotherapies at The Society for Immunotherapy of Cancer 36th Annual Meeting

Business Wire November 9, 2021

Precision BioSciences Appoints Sam Wadsworth, Ph.D. and Shari Lisa Piré, J.D. to Board of Directors

Business Wire November 8, 2021

Precision BioSciences Announces Two Oral Presentations Highlighting Updated Interim Data from Lead PBCAR0191 CAR T Immunotherapy for Relapsed and Refractory B-cell Malignancies at the 63rd Annual Meeting of the American Society of Hematology

Business Wire November 4, 2021

Precision BioSciences to Report Third Quarter 2021 Financial Results on November 10, 2021 and Participate in the Stifel 2021 Virtual Healthcare Conference on November 16, 2021

Business Wire November 3, 2021

Precision BioSciences to Present at the Jefferies Virtual Gene Therapy/Editing Summit on Thursday, October 27, 2021

Business Wire October 21, 2021

Precision BioSciences Announces Grant of Inducement Award for Newly Appointed Chief Executive Officer Pursuant to Nasdaq Listing Rule 5635(c)(4)

Business Wire September 27, 2021

Precision BioSciences Appoints Michael Amoroso Chief Executive Officer

Business Wire September 27, 2021

Precision BioSciences to Present at H.C. Wainwright 23rd Annual Global Investment Conference

Business Wire September 10, 2021

Precision BioSciences and iECURE Announce License and Collaboration Agreement to Develop ARCUS-Based Gene Editing Therapies

Business Wire September 9, 2021

Precision BioSciences Outlines Clinical Development Strategy for In Vivo Gene Editing Pipeline

Business Wire September 9, 2021

Precision BioSciences and Tiziana Life Sciences Announce Exclusive License Agreement to Evaluate Foralumab, a Novel, Fully Human Anti-CD3 Monoclonal Antibody, in Conjunction with Allogeneic CAR T Candidates for Cancer Treatment

GlobeNewswire September 2, 2021

Precision BioSciences to Host In Vivo Gene Editing R&D Event on September 9, 2021

Business Wire August 25, 2021

Pep Boys Celebrates 25 Years in Puerto Rico, 100 Years in Business, Opens First-Ever Service Center on U.S. Military Base

PR Newswire August 5, 2021

'Top Techs' Awarded at Pep Boys

PR Newswire June 10, 2021

Pep Boys to Award $100,000 in Scholarships to Aspiring Automotive Technicians

PR Newswire April 22, 2021